November 29, 2016 - By Linda Rogers · 0 Comments
The stock of Contrafect Corporation (NASDAQ:CFRX) registered a decrease of 9.48% in short interest. CFRX’s total short interest was 182,300 shares in November as published by FINRA. Its down 9.48% from 201,400 shares, reported previously. With 43,600 shares average volume, it will take short sellers 4 days to cover their CFRX’s short positions. The short interest to Contrafect Corporation’s float is 0.58%. ContraFect Corp (NASDAQ:CFRX) has declined 31.64% since April 26, 2016 and is downtrending. It has underperformed by 36.90% the S&P500.
Out of 3 analysts covering ContraFect (NASDAQ:CFRX), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. ContraFect has been the topic of 5 analyst reports since December 31, 2015 according to StockzIntelligence Inc. The company was initiated on Wednesday, September 28 by William Blair. The stock has “Buy” rating given by Maxim Group on Friday, July 22. Roth Capital downgraded the stock to “Neutral” rating in Tuesday, May 10 report. The stock of ContraFect Corp (NASDAQ:CFRX) earned “Buy” rating by Maxim Group on Thursday, December 31.
ContraFect Corporation, incorporated on March 5, 2008, is a clinical-stage biotechnology company. The Firm is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. The Firm focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The Company’s pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. The Company’s other product candidate includes CF-404.
Another recent and important ContraFect Corp (NASDAQ:CFRX) news was published by Quotes.Wsj.com which published an article titled: “ContraFect Corp. CFRX (US: Nasdaq)” on July 19, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers